Login to Your Account

Infinity, Novartis In $400M Deal For Inhibitors Of Bcl-2

By Karen Pihl-Carey

Tuesday, March 7, 2006
Tackling a family of proteins linked to cancer but long considered undruggable, Infinity Pharmaceuticals Inc. and Novartis AG signed a global development and commercialization deal potentially worth more than $400 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription